Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium

References

• Eriksson A, Cao R, Roy J, Tritsaris K, Wahlestedt C, Dissing S, et al. Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation. 2003; 107: 1532–8
   PubMed Web of Science ®Google Scholar
• Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999; 286: 2511–4
   PubMed Web of Science ®Google Scholar
• Thurston G. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat. 2002; 200: 575–80
   PubMed Web of Science ®Google Scholar
• Zhou, L, Ma, W, Yang, Z, Zhang, F, Lu, L, Ding, Z, et al. VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways. Gene Ther. 2005;12:196–202. Erratum in: Gene Ther. 2005; 12:552
   PubMed Web of Science ®Google Scholar
• Ferrarini, M, Arsic, N, Recchia, FA, Zentilin, L, Zacchigna, S, Xu, X, et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006;98:954–61, Epub 2006 Mar.
   PubMed Web of Science ®Google Scholar
• Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi A, et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther. 2003; 7: 450–9
   PubMed Web of Science ®Google Scholar
• Shyu KG, Chang H, Isner J M. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci. 2003; 73: 563–79
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001; 89: 477–9
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/surviving pathway. J Biol Chem. 2000; 275: 9102–5
   PubMed Web of Science ®Google Scholar
• Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitor. Nature. 2000; 408: 92–6
   PubMed Web of Science ®Google Scholar
• Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revasculariation. Trends Mol Med. 2003; 9: 109–17
   PubMed Web of Science ®Google Scholar
• Orlic D. Adult bone marrow stem cells regenerate myocardium in ischemic heart disease. Ann NY Acad Sci. 2003; 996: 152–7
   PubMed Web of Science ®Google Scholar
• Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney L A. The post-natal heart contains a myocardial stem cell population. FEBS Lett. 2002; 530: 239–43
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–7
   PubMed Web of Science ®Google Scholar
• Ziegler BL, Valtieri M, Porada GA, De Maria R, Muller R, Masella B, et al. KDR receptor: A key marker defining hematopoietic stem cells. Science. 1999; 285: 1553–8
   PubMed Web of Science ®Google Scholar
• Yuasa H, Takakura N, Shimomura T, Suenobu S, Yamada T, Nagayama H, et al. Analysis of human TIE2 function on hematopoietic stem cells in umbilical cord blood. Biochem Biophys Res Commun. 2002; 298: 731–7
   PubMed Web of Science ®Google Scholar
• Moore, MA, Hattori, K, Heissig, B, Shieh, JH, Dias, S, Crystal, RG, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and Angiopoietin-1. Ann NY Acad Sci. 2001;938:36–45; Discussion 45–7.
   PubMed Web of Science ®Google Scholar
• Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001; 193: 1005–14
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infracted myocardium. Pediatr Transplant. 2003; 7(Suppl 3)86–8
   PubMedGoogle Scholar
• Deb A, Wang S, Skelding KA, Miller D, Simper D, Caplice N M. Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation. 2003; 107: 1247–9
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001; 344: 1750–7
   PubMed Web of Science ®Google Scholar
• Duan HF, Wu CT, Wu DL, Lu Y, Liu HJ, Ha XQ, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther. 2003; 8: 467–74
   PubMed Web of Science ®Google Scholar
• Mangi, AA, Noiseux, N, Kong, D, He, H, Rezvani, M, Ingwall, JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infracted hearts, Nat Med. 2003;9:1195–201. Epub 2003 Aug 10.
   PubMed Web of Science ®Google Scholar
• Stewart, DJ, Hilton, JD, Arnold, JM, Gregoire, J, Rivard, A, Archer, SL, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment, Gene Ther 2006;13:1503–11. Epub 2006 Jun 22.
   PubMed Web of Science ®Google Scholar